Expand JNJ Menu
JNJ MENU

JNJ Latest Press Releases

-- November 22, 2024 --

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PRNewswire 8:00 AM

-- November 19, 2024 --

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting PRNewswire 9:02 AM

-- November 18, 2024 --

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results PRNewswire 4:30 PM

-- November 14, 2024 --

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjgren's disease study PRNewswire 10:00 AM

-- November 11, 2024 --

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjgren's disease PRNewswire 4:06 PM
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjgren's disease PRNewswire 4:05 PM
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjgren's disease PRNewswire 4:05 PM

-- November 8, 2024 --

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma PRNewswire 7:00 AM

-- November 7, 2024 --

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PRNewswire 8:00 AM

-- November 4, 2024 --

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare Globe Newswire 3:11 PM

-- October 28, 2024 --

TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease PRNewswire 7:30 AM

-- October 25, 2024 --

New SPECTREM study findings reveal TREMFYA (guselkumab) effectively clears overlooked and undertreated plaque psoriasis PRNewswire 8:05 AM

-- October 24, 2024 --

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress PRNewswire 8:00 AM

-- October 15, 2024 --

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson Business Wire 7:05 PM
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study PRNewswire 8:00 AM
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024 Business Wire 6:25 AM
Johnson & Johnson Reports Q3 2024 Results Business Wire 6:20 AM

-- October 10, 2024 --

Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference Business Wire 4:30 PM
TREMFYA (guselkumab) demonstrates impressive results across biologic-nave and biologic-refractory patients in Crohn's disease and ulcerative colitis PRNewswire 8:00 AM

-- October 9, 2024 --

Johnson & Johnson Completes Acquisition of V-Wave Business Wire 8:00 AM

-- October 4, 2024 --

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference Business Wire 4:30 PM
Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson Business Wire 1:37 PM

-- October 2, 2024 --

ERLEADA (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer PRNewswire 9:00 AM

-- September 30, 2024 --

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned PRNewswire 4:05 PM
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting PRNewswire 8:05 AM

-- September 27, 2024 --

CARVYKTI is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line PRNewswire 4:30 PM
DARZALEX (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma PRNewswire 1:05 PM
DARZALEX FASPRO-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned PRNewswire 1:00 PM
Novel combination of TALVEY (talquetamab-tgvs) and TECVAYLI (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease PRNewswire 8:05 AM
TALVEY (talquetamab-tgvs) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma PRNewswire 8:00 AM

-- September 20, 2024 --

Attorneys Vow to Oppose J&J's Third Bankruptcy Attempt Business Wire 6:53 PM
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims Business Wire 3:43 PM

-- September 19, 2024 --

RYBREVANT (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer PRNewswire 6:54 PM

-- September 16, 2024 --

Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer PRNewswire 2:50 AM

-- September 15, 2024 --

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer PRNewswire 2:30 AM

-- September 14, 2024 --

RYBREVANT (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer PRNewswire 9:45 AM
RYBREVANT (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer PRNewswire 3:10 AM

-- September 11, 2024 --

TREMFYA (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease PRNewswire 6:23 PM

-- September 10, 2024 --

Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT (amivantamab-vmjw) PRNewswire 5:15 PM

-- September 8, 2024 --

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer PRNewswire 1:47 PM

-- September 5, 2024 --

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results Business Wire 4:30 PM

-- August 29, 2024 --

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis PRNewswire 8:00 AM

-- August 27, 2024 --

Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress PRNewswire 8:00 AM

-- August 26, 2024 --

Johnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 Business Wire 8:00 AM

-- August 20, 2024 --

Johnson & Johnson to Acquire V-Wave Business Wire 7:30 AM
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer PRNewswire 7:00 AM

-- August 15, 2024 --

South Carolina Jury Awards $63.4 Million to Johnson & Johnson Asbestos Victim Business Wire 7:08 PM

-- August 13, 2024 --

Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy Business Wire 9:00 AM

-- August 7, 2024 --

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine PRNewswire 5:00 PM

-- August 6, 2024 --

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities Globe Newswire 9:00 AM

-- July 30, 2024 --

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible PRNewswire 6:42 PM

-- July 29, 2024 --

Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference Business Wire 4:00 PM

-- July 26, 2024 --

Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan Business Wire 9:38 AM
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan Business Wire 9:05 AM

-- July 23, 2024 --

Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Business Wire 4:00 PM

-- July 22, 2024 --

Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan Business Wire 11:59 AM
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression PRNewswire 8:00 AM

-- July 17, 2024 --

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 Business Wire 6:25 AM
Johnson & Johnson reports Q2 2024 results Business Wire 6:20 AM

-- July 15, 2024 --

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors Globe Newswire 8:05 AM

-- July 11, 2024 --

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 Business Wire 7:30 AM

-- July 2, 2024 --

CARVYKTI (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study PRNewswire 7:30 AM

-- June 28, 2024 --

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients PRNewswire 11:30 AM

-- June 27, 2024 --

Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue Business Wire 6:46 PM